Studying how people with multiple sclerosis use Ocrevus Zunovo
Looks at experiences with Ocrevus Zunovo in adults with multiple sclerosis.
Plain-language title generated from the registry record
Registry title: Ocrevus Zunovo for MS: Mixed Methods
Key facts
- Where
- Chicago, United StatesSee the site
Where in United States
- Northwestern Memorial HospitalChicago, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Northwestern University
- Trial code
- NCT07710105
- Record updated
- 20 July 2026
- Original description
Ocrevus Zunovo implementation, feasibility, acceptability, patient satisfaction, treatment persistence, and impact on MS disease outcomes will be analyzed in this mixed methods study. This study will incorporate clinical data and questionnaire results from MS patients who take Ocrevus Zunovo as well as qualitative interviews with MS patients, family members, and other individuals involved in Ocrevus Zunovo treatment. The purpose of this study is to synthesize implementation strategies that improve patient access to high-efficacy MS therapies in real-world settings.Read full original descriptionShow less
Ocrevus Zunovo for Patients With Multiple Sclerosis: Mixed Methods on Barriers and Facilitators to Use and Retention
Ocrevus Zunovo implementation, feasibility, acceptability, patient satisfaction, treatment persistence, and impact on MS disease outcomes will be analyzed in this mixed methods study. This study will incorporate clinical data and questionnaire results from MS patients who take Ocrevus Zunovo as well as qualitative interviews with MS patients, family members, and other individuals involved in Ocrevus Zunovo treatment. The purpose of this study is to synthesize implementation strategies that improve patient access to high-efficacy MS therapies in real-world settings.
Inclusion: Age of 18 years or older; Resident of the USA; Seen at Northwestern Medicine; Meets diagnostic criteria (2024) for MS, either RMS or PPMS; Diagnosis of MS (G35) on file by a neurologist; Wants to start or restart a DMT for MS; Willing to be in a 12-month follow up study.
Exclusion: Current participant in an MS or any experimental therapy clinical trial; Currently taking a DMT that has not been washed out (e.g. recent treatment with Cladribine, Natalizumab, sphingosine 1-phosphate inhibitor, implying the last DMT is still actively immunosuppressing the patient); Current chemotherapy; Prior allergic reaction or intolerance to Ocrelizumab IV or SubQ or any monoclonal antibody therapy; History of stem cell transplant, CAR-T or other chemo-ablative procedures; Active hepatitis or latent hepatitis B; Tuberculosis; Current serious infection, e.g. COVID-19, shingles, active pneumonia, progressive multifocal leukoencephalopathy, etc; Unclear diagnosis of MS; Incarcerated; Unable to provide informed consent; Moribund; Unable to speak a language for which consent processes are available at Northwestern Hospitals; Unwilling to complete surveys over the course of the following 12 months; No access to computer or telephone; Hypogammaglobulinemia IgG level <500; Leukopenia <2.0; Elevated liver enzymes 3 times the upper limit of normal; Currently pregnant, breastfeeding, or a person of childbearing capacity who is sexually active without a documented plan of current contraceptive methods; Any other diagnosis or reason deemed to make the participant unfit for participation by the study PI.